Patents by Inventor Nicolas Soldermann
Nicolas Soldermann has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20250059181Abstract: The invention relates to substituted tetrahydro-pyrido-pyrimidine derivatives of the formula (I), wherein Y, R1, R2 and m are as defined in the description. Such compounds are suitable for the treatment of a disorder or disease which is mediated by the activity of the PI3K enzymes.Type: ApplicationFiled: November 8, 2023Publication date: February 20, 2025Applicant: Novartis AGInventors: Nigel Graham Cooke, Paulo Fernandes Gomes dos Santos, Nadege Graveleau, Christina Hebach, Klemens Högenauer, Gregory Hollingworth, Alexander Baxter Smith, Nicolas Soldermann, Frank Stowasser, Ross Sinclair Strang, Nicola Tufilli, Anette Von Matt, Romain Wolf, Frédéric Zecri
-
Publication number: 20240382457Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing said compound, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition comprising said compound.Type: ApplicationFiled: July 18, 2024Publication date: November 21, 2024Inventors: Vincent BORDAS, Cara BROCKLEHURST, Patrick CHENE, Pascal FURET, Vito GUAGNANO, Patricia IMBACH-WEESE, Joerg KALLEN, Mickael LE DOUGET, Edwige Liliane Jeanne LORTHIOIS, Joseph MCKENNA, Bahaa SALEM, Tobias SCHMELZLE, Holger SELLNER, Nicolas SOLDERMANN, Markus VOEGTLE, Markus WARTMANN
-
Publication number: 20240382600Abstract: The present disclosure relates to a conjugate comprising a YAP/TAZ-TEAD Protein Protein Interaction Inhibitor (PPII) linked to a Ligase Binder via a linker, or a pharmaceutically acceptable salt thereof, as well as methods of using such conjugates.Type: ApplicationFiled: August 30, 2022Publication date: November 21, 2024Inventors: Emilie CHAPEAU, Patrick CHENE, Pascal FURET, Laurence KIEFFER, Rainer MACHAUER, Anne PICARD, Tobias SCHMELZLE, Holger SELLNER, Nicolas SOLDERMANN, Markus VOEGTLE, Markus WARTMANN
-
Patent number: 12083101Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing said compound, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition comprising said compound.Type: GrantFiled: March 15, 2021Date of Patent: September 10, 2024Assignee: Novartis AGInventors: Vincent Bordas, Cara Brocklehurst, Patrick Chene, Pascal Furet, Vito Guagnano, Patricia Imbach-Weese, Joerg Kallen, Mickael Le Douget, Edwige Liliane Jeanne Lorthiois, Joseph McKenna, Bahaa Salem, Tobias Schmelzle, Holger Sellner, Nicolas Soldermann, Markus Voegtle, Markus Wartmann
-
Publication number: 20220267318Abstract: The invention relates to substituted tetrahydro-pyrido-pyrimidine derivatives of the formula (I), wherein Y, R1, R2 and m are as defined in the description. Such compounds are suitable for the treatment of a disorder or disease which is mediated by the activity of the PI3K enzymes.Type: ApplicationFiled: August 11, 2021Publication date: August 25, 2022Applicant: Novartis AGInventors: Nigel Graham Cooke, Paulo Fernandes Gomes Dos Santos, Nadege Graveleau, Christina Hebach, Klemens Hoegenauer, Gregory John Hollingworth, Alexander Baxter Smith, Nicolas Soldermann, Frank Stowasser, Ross Sinclair Strang, Nicola Tufilli, Anette von Matt, Romain Wolf, Frederic Zecri
-
Publication number: 20210299100Abstract: The present invention provides a compound of formula (1) or a pharmaceutically acceptable salt thereof; a method for manufacturing said compound, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition comprising said compound.Type: ApplicationFiled: March 15, 2021Publication date: September 30, 2021Inventors: Vincent BORDAS, Cara BROCKLEHURST, Patrick CHENE, Zhongbo FEI, Pascal FURET, Vito GUAGNANO, Patricia IMBACH-WEESE, Joerg KALLEN, Mickael LE DOUGET, Jialiang LI, Wei LI, Edwige Liliane Jeanne LORTHIOIS, Joseph McKENNA, Bahaa SALEM, Tobias SCHMELZLE, Holger SELLNER, Nicolas SOLDERMANN, Markus VOEGTLE, Markus WARTMANN
-
Publication number: 20200392132Abstract: The invention relates to substituted tetrahydro-pyrido-pyrimidine derivatives of the formula (I), wherein Y, R1, R2 and m are as defined in the description. Such compounds are suitable for the treatment of a disorder or disease which is mediated by the activity of the PI3K enzymes.Type: ApplicationFiled: June 30, 2020Publication date: December 17, 2020Applicant: Novartis AGInventors: Nigel Graham Cooke, Paulo Fernandes Gomes Dos Santos, Nadege Graveleau, Christina Hebach, Klemens Hoegenauer, Gregory John Hollingworth, Alexander Baxter Smith, Nicolas Soldermann, Frank Stowasser, Ross Sinclair Strang, Nicola Tufilli, Anette von Matt, Romain Wolf, Frederic Zecri
-
Publication number: 20190218217Abstract: The invention relates to substituted tetrahydro-pyrido-pyrimidine derivatives of the formula (I), wherein Y, R1, R2 and m are as defined in the description. Such compounds are suitable for the treatment of a disorder or disease which is mediated by the activity of the PI3K enzymes.Type: ApplicationFiled: March 28, 2019Publication date: July 18, 2019Inventors: Nigel Graham Cooke, Paulo Fernandes Gomes Dos Santos, Nadege Graveleau, Christina Hebach, Klemens Hoegenauer, Gregory John Hollingworth, Alexander Baxter Smith, Nicolas Soldermann, Frank Stowasser, Ross Sinclair Strang, Nicola Tufilli, Anette von Matt, Romain Wolf, Frederic Zecri
-
Publication number: 20190040061Abstract: The invention relates to substituted tetrahydro-pyrido-pyrimidine derivatives of the formula (I), wherein Y, R1, R2 and m are as defined in the description. Such compounds are suitable for the treatment of a disorder or disease which is mediated by the activity of the PI3K enzymes.Type: ApplicationFiled: October 17, 2018Publication date: February 7, 2019Inventors: Nigel Graham Cooke, Paulo Fernandes Gomes Dos Santos, Nadege Graveleau, Christina Hebach, Klemens Hoegenauer, Gregory John Hollingworth, Alexander Baxter Smith, Nicolas Soldermann, Frank Stowasser, Ross Sinclair Strang, Nicola Tufilli, Anette von Matt, Romain Wolf, Frederic Zecri
-
Publication number: 20180265509Abstract: The invention relates to substituted tetrahydro-pyrido-pyrimidine derivatives of the formula (I), wherein Y, R1, R2 and m are as defined in the description. Such compounds are suitable for the treatment of a disorder or disease which is mediated by the activity of the PI3K enzymes.Type: ApplicationFiled: May 30, 2018Publication date: September 20, 2018Inventors: Nigel Graham Cooke, Paulo Fernandes Gomes Dos Santos, Nadege Graveleau, Christina Hebach, Klemens Hoegenauer, Gregory John Hollingworth, Alexander Baxter Smith, Nicolas Soldermann, Frank Stowasser, Ross Sinclair Strang, Nicola Tufilli, Anette von Matt, Romain Wolf, Frederic Zecri
-
Patent number: 9949979Abstract: The invention relates to new uses of PI3K inhibitors, wherein said inhibitors have an inhibitory action on the PI3K isoform delta for the treatment of immunopathology in a subject suffering from a disease or disorder selected from malaria, leishmaniasis, trypanosomiasis, toxoplasmosis and/or neurocysticercosis, via functional inhibition of TLR9 of the infected subject.Type: GrantFiled: December 14, 2012Date of Patent: April 24, 2018Assignee: Novartis AGInventors: Nigel Graham Cooke, Paulo Antonio Fernandes Gomes Dos Santos, Pascal Furet, Christina Hebach, Klemens Hoegenauer, Gregory Hollingworth, Christoph Kalis, Ian Lewis, Alexander Baxter Smith, Nicolas Soldermann, Frederic Stauffer, Ross Strang, Frank Stowasser, Nicola Tuffilli, Anette Von Matt, Romain Wolf, Frederic Zecri
-
Patent number: 9840498Abstract: Provided are substituted quinazolin-4-one compounds of the formula (I) and/or pharmaceutically acceptable salts and/or solvates thereof, wherein R1, R2, R3, R5, R6 and L are as defined in the description. Such compounds are suitable for the treatment of a disorder or disease which is mediated by the activity of the class I PI3K kinases.Type: GrantFiled: July 24, 2014Date of Patent: December 12, 2017Assignee: Novartis AGInventors: Zhenxing Du, Samuel Hintermann, Konstanze Hurth, Sébastien Jacquier, Hansjoerg Lehmann, Henrik Moebitz, Nicolas Soldermann, Aleksandar Stojanovic
-
Publication number: 20170267678Abstract: The invention relates to substituted tetrahydro-pyrido-pyrimidine derivatives of the formula (I), wherein Y, R1, R2 and m are as defined in the description. Such compounds are suitable for the treatment of a disorder or disease which is mediated by the activity of the PI3K enzymes.Type: ApplicationFiled: June 5, 2017Publication date: September 21, 2017Applicant: Novartis AGInventors: Nigel Graham COOKE, Paulo Fernandes Gomes Dos Santos, Nadege GRAVELEAU, Christina HEBACH, Klemens HOEGENAUER, Gregory John HOLLINGWORTH, Alexander Baxter SMITH, Nicolas SOLDERMANN, Frank STOWASSER, Ross Sinclair STRANG, Nicola TUFILLI, Anette von MATT, Romain WOLF, Frederic ZECRI
-
Patent number: 9763952Abstract: The invention relates to dihydro-benzo-oxazine and dihydro-pyrido-oxazine compounds of the formula (I) and/or pharmaceutically acceptable salts and/or solvates thereof, wherein Y, V, W, U, Q, R1, R5, R7 and R30 are as defined in the description. Such compounds are suitable for the treatment of a disorder or disease which is mediated by the activity of the PI3K enzymes.Type: GrantFiled: December 21, 2015Date of Patent: September 19, 2017Assignee: NOVARTIS AGInventors: Giorgio Caravatti, Sylvie Chamoin, Pascal Furet, Klemens Hogenauer, Konstanze Hurth, Karen Kammertoens, Ian Lewis, Henrik Moebitz, Alexander Baxter Smith, Nicolas Soldermann, Romain Wolf, Frederic Zecri
-
Patent number: 9539260Abstract: The invention relates to dihydro-benzo-oxazine and dihydro-pyrido-oxazine compounds of the formula (I) and/or pharmaceutically acceptable salts and/or solvates thereof, wherein Y, V, W, U, Q, R1, R5, R7 and R30 are as defined in the description. Such compounds are suitable for the treatment of a disorder or disease which is mediated by the activity of the PI3K enzymes.Type: GrantFiled: December 20, 2012Date of Patent: January 10, 2017Assignee: NOVARTIS AGInventors: Giorgio Caravatti, Sylvie Chamoin, Pascal Furet, Klemens Hogenauer, Konstanze Hurth, Karen Kammertoens, Ian Lewis, Henrik Moebitz, Alexander Baxter Smith, Nicolas Soldermann, Romain Wolf, Frederic Zecri
-
Patent number: 9499536Abstract: The invention relates to substituted tetrahydro-pyrido-pyrimidine derivatives of the formula (I), wherein Y, R1, R2 and m are as defined in the description. Such compounds are suitable for the treatment of a disorder or disease which is mediated by the activity of the PI3K enzymes.Type: GrantFiled: January 9, 2014Date of Patent: November 22, 2016Assignee: Novartis AGInventors: Nigel Graham Cooke, Frédèric Zecri, Nicolas Soldermann, Romain Wolf, Christina Hebach, Klemens Hoegenauer, Gregory John Hollingworth, Anette Von Matt, Ross Sinclair Strang, Alexander Baxter Smith, Paulo Fernandes Gomes Dos Santos, Nadege Graveleau, Frank Stowasser, Nicola Tufilli
-
Publication number: 20160168131Abstract: Provided are substituted quinazolin-4-one compounds of the formula (I) and/or pharmaceutically acceptable salts and/or solvates thereof, wherein R1, R2, R3, R5, R6 and L are as defined in the description. Such compounds are suitable for the treatment of a disorder or disease which is mediated by the activity of the class I PI3K kinases.Type: ApplicationFiled: July 24, 2014Publication date: June 16, 2016Applicant: NOVARTIS AGInventors: Zhenxing DU, Samuel HINTERMANN, Konstanze HURTH, Sébastien JACQUIER, Hansjoerg LEHMANN, Henrik MOEBITZ, Nicolas SOLDERMANN, Aleksandar STOJANOVIC
-
Publication number: 20160106753Abstract: The invention relates to dihydro-benzo-oxazine and dihydro-pyrido-oxazine compounds of the formula (I) and/or pharmaceutically acceptable salts and/or solvates thereof, wherein Y, V, W, U, Q, R1, R5, R7 and R30 are as defined in the description. Such compounds are suitable for the treatment of a disorder or disease which is mediated by the activity of the PI3K enzymes.Type: ApplicationFiled: December 21, 2015Publication date: April 21, 2016Applicant: Novartis AGInventors: Giorgio CARAVATTI, Sylvie CHAMOIN, Pascal FURET, Klemens HOGENAUER, Konstanze HURTH, Christoph KALIS, Karen KAMMERTOENS, Ian LEWIS, Henrik MOEBITZ, Alexander Baxter SMITH, Nicolas SOLDERMANN, Romain WOLF, Frederic ZECRI
-
Publication number: 20150342951Abstract: The invention relates to new uses of PI3K inhibitors, wherein said inhibitors have an inhibitory action on the PI3K isoform delta for the treatment of immunopathology in a subject suffering from a disease or disorder selected from malaria, leishmaniasis, trypanosomiasis, toxoplasmosis and/or neurocysticercosis, via functional inhibition of TLR9 of the infected subject.Type: ApplicationFiled: December 14, 2012Publication date: December 3, 2015Applicant: NOVARTIS AGInventors: Nigel Graham COOKE, Paulo Antonio FERNANDES GOMES DOS SANTOS, Pascal FURET, Christina HEBACH, Klemens HOGENAUER, Gregory HOLLINGWORTH, Christoph KALIS, Ian LEWIS, Alexander Baxter SMITH, Nicolas SOLDERMANN, Frederic STAUFFER, Ross STRANG, Frank STOWASSER, Nicola TUFFILLI, Anette VON MATT, Romain WOLF, Frederic ZECRI
-
Publication number: 20150148377Abstract: The invention relates to quinoline compounds of the formula (I) and/or pharmaceutically acceptable salts and/or solvates thereof, wherein Y, W, U, Q, R1, R5 R7 and R30 are as defined in the description. Such compounds are suitable for the treatment of a disorder or disease which is mediated by the activity of the PI3K enzymes.Type: ApplicationFiled: December 20, 2012Publication date: May 28, 2015Applicant: NOVARTIS AGInventors: Klemens Hogenauer, Konstanze Hurth, Christoph Kalis, Henrik Moebitz, Nicolas Soldermann, Frederic Zecri